| Chronic Lymphocytic Leukemia
Brukinsa vs Calquence Tablets
Side-by-side clinical, coverage, and cost comparison for chronic lymphocytic leukemia.Deep comparison between: Brukinsa vs Calquence with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCalquence has a higher rate of injection site reactions vs Brukinsa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Calquence but not Brukinsa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Brukinsa
Calquence
At A Glance
Oral
Once or twice daily
BTK inhibitor
Oral
Every 12 hours
BTK inhibitor
Indications
- Mantle cell lymphoma
- Waldenstrom Macroglobulinemia
- Marginal Zone B-Cell Lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Lymphoma, Follicular
- Mantle cell lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Dosing
Mantle cell lymphoma, Waldenstrom Macroglobulinemia, Marginal Zone B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma 160 mg orally twice daily or 320 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.
Lymphoma, Follicular 160 mg orally twice daily in combination with obinutuzumab, with or without food, until disease progression or unacceptable toxicity.
Mantle cell lymphoma 100 mg orally approximately every 12 hours until disease progression or unacceptable toxicity; swallow tablet whole with or without food (monotherapy or in combination with bendamustine and rituximab).
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma 100 mg orally approximately every 12 hours until disease progression or unacceptable toxicity (monotherapy, or in combination with obinutuzumab or venetoclax).
Contraindications
—
—
Adverse Reactions
Most common (>=30%) Neutrophil count decreased, platelet count decreased, upper respiratory tract infection, hemorrhage, musculoskeletal pain
Serious Hemorrhage, pneumonia, cytopenias, second primary malignancies, cardiac arrhythmias, hepatotoxicity including drug-induced liver injury
Postmarketing Drug-induced liver injury
Most common (>=30%) Upper respiratory tract infection, diarrhea, headache, musculoskeletal pain.
Serious Serious and opportunistic infections, hemorrhage, cytopenias, second primary malignancies, cardiac arrhythmias, hepatotoxicity including drug-induced liver injury.
Postmarketing Ventricular arrhythmias, drug induced liver injury.
Pharmacology
Zanubrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK) that forms a covalent bond with a cysteine residue in the BTK active site, inhibiting BTK activity and thereby blocking B-cell proliferation, trafficking, chemotaxis, and adhesion pathways driven by B-cell antigen receptor and cytokine receptor signaling.
Acalabrutinib is a small-molecule inhibitor of Bruton tyrosine kinase (BTK); it and its active metabolite ACP-5862 form a covalent bond with a cysteine residue in the BTK active site, inhibiting BTK enzymatic activity and downstream B-cell proliferation, trafficking, chemotaxis, and adhesion pathways required for B-cell malignancy growth.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Brukinsa
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Calquence
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Brukinsa
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (5/8) · Qty limit (4/8)
Calquence
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Brukinsa
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Calquence
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Brukinsa.
Cost estimate not availableAssistance Fund: Chronic Lymphocytic Leukemia (CLL)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BrukinsaView full Brukinsa profile
CalquenceView full Calquence profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.